

ACRUX ANNOUNCES HALF-YEAR EARNINGS CALL

Acrux (ASX: ACR) today confirmed an earnings call for the six months ended 31 December 2014 is scheduled on Thursday 26 February 2015 at 10am.

Investors are now welcome to register for this event via our website www.acrux.com.au under the Investors tab.

Contact

Michael Kotsanis, CEO and Managing Director: 03 8379 0100

Sharon Papworth, CFO and Company Secretary: 03 8379 0100

About Acrux

www.acrux.com.au

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology.
- The Acrux technology, used in marketed products including Axiron®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.
- Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.